jump to content jump to footer
Radiologist analyzing whole-body MRI scans of prostate cancer bone metastases using AI-assisted tumor load quantification in mint Lesion

AI-Supported Tumor Load Quantification for Bone Metastasis in Prostate Cancer

To assess treatment response in patients with advanced prostate cancer, radiologists rely on advanced medical imaging. Conventional modalities, such as bone scans and CT, present limitations in detecting early disease progression and lack standardized criteria for evaluating therapy response [1]. By utilizing Whole-Body MRI, radiologists can detect and monitor metastatic spread patterns, evaluating tumor load non-invasively, radiation free, and without the use of contrast agents or tracers.

However, translating this imaging data into routine clinical insights presents significant workflow hurdles:

  • Manual delineation of bone metastasis is a time-consuming process that often takes an hour or more per scan [2].
  • Even semi-automated tools can require between 12 and 23 minutes to finalize results, making routine use difficult [2].
  • Without structured data, assessing therapy effectiveness across multiple time points can be inconsistent.

AI Capabilities Integrated into mint Lesion

To streamline this process, a specialized AI algorithm*, developed in collaboration with The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, has been integrated into mint Lesion. This software solution supports the radiologists by addressing core computational and reporting steps:

  • Targeted Data Extraction: The software extracts total diffusion volume (TDV) and global ADC (gADC) statistics for both the whole skeleton and specific body regions, presenting these measurements in a structured report with color-coded visualizations.
  • Automated Computation: Execute the computation pipeline for tumor load quantification in approximately 90 seconds [2], supported by the AI workflow.
  • Comprehensive Workflow Execution: Complete the full automated workflow, including pre- and post-treatment analysis alongside structured reporting, in approximately three minutes [2].
  • Consistent Therapy Evaluation: Evaluate treatment response across multiple time points, utilizing a structured framework that facilitates reliable longitudinal insights.

Practical Outcomes for Clinical Workflows

Supported by the AI-powered mint Lesion software, radiologists can incorporate full tumor load quantification into standard clinical workflows and maintain reproducible procedures across different scans and time points. Ultimately, this equips them to supply the tumor board with structured, objective data to evaluate therapy effectiveness, providing a factual basis for decisions regarding ongoing patient care.

Interested in AI-supported quantification in other hematologic-oncologic applications? Learn how mint Lesion supports structured assessment in multiple myeloma.

 

*based on research funded by the National Institute for Health and Care Research (NIHR)

 

Interested in learning how AI-supported structured reporting can support your clinical workflows? Get in touch with our team to learn more about mint Lesion.

References

[1] Padhani, AR, Lecouvet, FE, Tunariu, N, Koh, DM, De Keyzer, F, Collins, DJ, Sala, E, Schlemmer, HP,  Petralia, G, Vargas, HA, Fanti, S, Tombal HB, de Bono, J (2017). METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. European Urology, 71(1), 81-92. DOI: 10.1016/j.eururo.2016.05.033. PMID 27317091.

[2] Candito A, Blackledge MD, Holbrey R, Porta N, Ribeiro A, Zugni F, D'Erme L, Castagnoli F, Dragan A, Donners R, Messiou C, Tunariu N, Koh DM. AI-driven software for automated quantification of skeletal metastases and treatment response evaluation using whole-body diffusion-weighted MRI (WB-DWI) in advanced prostate cancer. Phys Med Biol. 2025 Nov 14;70(22). DOI: 10.1088/1361-6560/ae19c5. PMID: 41166885.

Streamline Prostate Cancer Screenings with Prostate.Carcinoma.ai in mint Lesion
The Prostate.Carcinoma.ai plug-in, developed by our partner FUSE-AI, is a powerful addition to mint Lesion, designed specifically to enhance prostate…
Read more
Leverage Advanced AI-Driven Nodule Detection and Analysis for Comprehensive Patient Care
Discover the power of streamlined AI-driven lung screening with contextflow ADVANCE Chest CT integrated into mint Lesion. With automated lung nodule…
Read more
Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer
In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing…
Read more
scroll-top